Therapeutic Targets of KRAS in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS- mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Other approaches under investigation to target mutant KRAS in CRC include perturbing the interaction between KRAS and the plasma membrane, and the combined inhibition of downstream pathways [122].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Calcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462 · cited 1×
“3′ untranslated region (UTR) of a target gene leading to either degradation of mRNA or inhibition of translation [82].”
BackgroundSeger, R., & Krebs, E. G. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.9.7601337 · Cited by 3,602 · cited 2×
“The RAS activates multiple downstream pathways including the RAS-RAFMEK-ERK pathway, which regulates cell cycle and proliferation [22].”
BackgroundThe role of MicroRNAs in human cancer
Peng, Y., & Croce, C. M. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2015.4 · Cited by 2,483 · cited 1×
“Multiple studies have elucidated the critical role of miRNAs in cell proliferation, migration, invasion, apoptosis, and angiogenesis [83].”
BackgroundThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., van Boom, J. H., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860 · cited 1×
“In Colon cancers, approximately 45% of the cases carry a KRAS mutation [11,12].”
BackgroundAll ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,799 · cited 1×
“KRAS and other RAS oncogenes are intracellular guanine nucleotide-binding proteins (G proteins) that belong to the family of small GTPases and function as GDP/GTPregulated molecular switches [21].”
BackgroundKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733 · cited 1×
“Although the KRAS G12C is noted only in 1–3% of CRC, the recent promising clinical data breaks the assumption of KRAS being undruggable [32].”
BackgroundT-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · cited 2×
“They reported objective regression of all seven lung metastatic lesions from underlying CRC after the infusion of KRAS G12D directed TILs [95].”
BackgroundThe Ras superfamily at a glance
Wennerberg, K., Rossman, K. L., & Der, C. J. (2005) · Journal of Cell Science · doi:10.1242/jcs.01660 · Cited by 1,352 · cited 1×
“Overall, the RAS family constitutes 36 human genes, but KRAS, HRAS, and NRAS by far are the most prominent ones involved in human cancer [19].”
BackgroundDNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 1×
“proved that these proto-oncogenes could transform into oncogenes after acquiring mutations and these oncogenes can be virally transmitted [16].”
BackgroundHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 1×
“It works by irreversibly and selectively binding to KRAS G12C in its inactive state, blocking its signaling to other cells, thus preventing tumor cell growth and proliferation, leading to cancer cell death [33].”
BackgroundMicrosatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063 · cited 2×
“Mutations in any of the four mismatch repair genes (hMLH1, hMSH2, hMSH6, and hPMS2) result in the microsatellite instability and leads to the development of the hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome [5].”
BackgroundThe Chromosomal Instability Pathway in Colon Cancer
Pino, M. S., & Chung, D. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.065 · Cited by 932 · cited 2×
“These karyotypic changes coupled with the mutations in the tumor suppressor and oncogenes (APC, KRAS, DCC/SMAD4, and TP53) activate oncogenic pathways critical to the pathogenesis of CRC [4].”
BackgroundThe PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878 · cited 2×
“These pathways also provide compensatory signaling when either one is inhibited [71].”
BackgroundModelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817 · cited 1×
“Several studies in mouse models have demonstrated the importance of MYC in KRAS-driven oncogenesis and genetic suppression of MYC impairing the growth of KRAS-driven cancer cells [87,88].”
BackgroundAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · cited 1×
“It traps the KRAS in the inactive GDP-bound state [29].”
BackgroundErrors in DNA replication as a basis of malignant changes.
Loeb, L. A., Springgate, C. F., & Battula, N. (1974) · PubMed · Cited by 619
Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D., Brandhuber, B. J., Gross, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578 · cited 1×
“AZD6244 (Selumetinib) is an oral selective mitogen-activated protein kinase kinase (MAPKK, or MEK) pathway inhibitor and targets MEK1 and MEK2 [74].”
BackgroundAn Unidentified Virus which causes the Rapid Production of Tumours in Mice
HARVEY, J. J. (1964) · Nature · doi:10.1038/2041104b0 · Cited by 555 · cited 1×
“The viral inoculum from leukemic rats was observed to induce sarcoma in newborn rats [14,15].”
BackgroundRole of miR-143 targeting KRAS in colorectal tumorigenesis
Chen, X., Guo, X., Zhang, H., Xiang, Y., Chen, J., Yin, Y., Cai, X., Wang, K., Wang, G., Ba, Y., et al. (2009) · Oncogene · doi:10.1038/onc.2008.474 · Cited by 549 · cited 1×
“However, when miR-143 inhibitor was used it stimulated cell proliferation and increased the KRAS protein level [85].”
BackgroundAnnual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics
Islami, F., Ward, E. M., Sung, H., Cronin, K. A., Tangka, F. K. L., Sherman, R. L., Zhao, J., Anderson, R. N., Henley, S. J., Yabroff, K. R., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab131 · Cited by 478
Making sense of G‐quadruplex and i‐motif functions in oncogene promoters
Brooks, T. A., Kendrick, S., & Hurley, L. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07759.x · Cited by 477
Hall, A., Marshall, C. J., Spurr, N. K., & Weiss, R. A. (1983) · Nature · doi:10.1038/303396a0 · Cited by 442 · cited 1×
“Later in 1983, the human sequences homologous to NRAS were described in human sarcoma cell lines [18].”
BackgroundShimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431 · cited 1×
“showed combined blockage using a PI3K pathway inhibitor in combination with a MAPK pathway inhibitor in advanced solid tumors including CRC observed tumor regression ranging between 2% and 64% [78].”
MethodClinical Relevance of KRAS in Human Cancers
Jančík, S., Drábek, J., Radzioch, D., & Hajdúch, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/150960 · Cited by 402 · cited 2×
“1 and encodes a 188–amino acid residues [20].”
BackgroundLu, Y.-C., Yao, X., Crystal, J. S., Li, Y. F., El-Gamil, M., Gross, C., Davis, L., Dudley, M. E., Yang, J. C., Samuels, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0433 · Cited by 401 · cited 1×
“Adoptive cell therapy (ACT) uses ex-vivo expanded tumor-reactive T-cells administered to an adequately prepared recipient [93].”
BackgroundDavies, B. R., Logie, A., McKay, J. S., Martin, P., Steele, S., Jenkins, R., Cockerill, M., Cartlidge, S., & Smith, P. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0231 · Cited by 387 · cited 1×
“Pre-clinical studies with AZD6244 have shown regression of tumors both in KRAS wild-type BxPC3 pancreatic tumor xenograft model, as well as in colorectal, pancreatic, non-small cell lung, hepatocellular, and melanoma human xenograft models [75].”
MethodPolo-like kinases (Plks) and cancer
Takai, N., Hamanaka, R., Yoshimatsu, J., & Miyakawa, I. (2005) · Oncogene · doi:10.1038/sj.onc.1208272 · Cited by 386 · cited 1×
“It has been found to be overexpressed in multiple cancer types including CRC [39].”
BackgroundFrequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
Vaughn, C. P., ZoBell, S. D., Furtado, L. V., Baker, C. L., & Samowitz, W. S. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20854 · Cited by 377 · cited 1×
“The RAS mutations are common in CRC (~45%), with KRAS being the most prevalent (85%), followed by NRAS (15%) and HRAS (1%) [25].”
BackgroundYou, M., Yu, D.-H., & Feng, G.-S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.2416 · Cited by 364 · cited 1×
“It is involved in various intracellular oncogenic signaling pathways, including the RAS/Raf/MAPK [46,47], PI3K/AKT [48], Jak/STAT [49], PD-1/PD-L1 [50], and mTOR pathways [51].”
BackgroundMetabolic Pathways Regulating Colorectal Cancer Initiation and Progression
La Vecchia, S., & Sebastián, C. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.018 · Cited by 349 · cited 1×
“Apart from the above described pathogenic mechanisms, recent studies have shown the alteration in the various metabolic pathways including glycolysis, pyruvate oxidation, lactate oxidation, mitochondrial activity, and glutamine and cholesterol metabolism are involved in the initiation and progression of CRC [7].”
BackgroundTiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism
Lambert, J. M., Lambert, Q. T., Reuther, G. W., Malliri, A., Siderovski, D. P., Sondek, J., Collard, J. G., & Der, C. J. (2002) · Nature Cell Biology · doi:10.1038/ncb833 · Cited by 326 · cited 1×
“The RAS-related protein (RAL) pathway and the tumor invasion and metastasis-inducing protein 1 (TIAM1-RAC1) are involved in intracellular vesicle trafficking, cytoskeletal organization, and tumor growth [23].”
BackgroundChandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315 · cited 1×
“Apart from playing critical role in the signal transduction involving multiple intracellular pathways, oncogenic KRAS is known to dysregulate various metabolic processes including glutaminolysis, glycolysis, and redox hemostasis promoting tumorigenesis and chemoresistance [24].”
BackgroundKRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301 · cited 1×
“Subsequently, in 1982, the human HRAS and KRAS oncogene sequences were ascertained in human bladder and lung cancer cell lines, respectively [17].”
BackgroundInhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Soucek, L., Whitfield, J. R., Sodir, N. M., Massó-Vallés, D., Serrano, E., Karnezis, A. N., Swigart, L. B., & Evan, G. I. (2013) · Genes & Development · doi:10.1101/gad.205542.112 · Cited by 301 · cited 2×
“Several studies in mouse models have demonstrated the importance of MYC in KRAS-driven oncogenesis and genetic suppression of MYC impairing the growth of KRAS-driven cancer cells [87,88].”
BackgroundWildtype Kras2 can inhibit lung carcinogenesis in mice
Zhang, Z., Wang, Y., Vikis, H. G., Johnson, L., Liu, G., Li, J., Anderson, M. W., Sills, R. C., Hong, H. L., Devereux, T. R., et al. (2001) · Nature Genetics · doi:10.1038/ng721 · Cited by 296
Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J., & Park, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8513-8525.2000 · Cited by 286 · cited 1×
“It is involved in various intracellular oncogenic signaling pathways, including the RAS/Raf/MAPK [46,47], PI3K/AKT [48], Jak/STAT [49], PD-1/PD-L1 [50], and mTOR pathways [51].”
BackgroundFrom Plk1 to Plk5: Functional evolution of polo-like kinases
de Cárcer, G., Manning, G., & Malumbres, M. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16494 · Cited by 273
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201414 · Cited by 265
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
ALLEN, L. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.012 · Cited by 257 · cited 2×
“The RAS/RAF/MEK/ERK and PI3K/AKT/mTOR are two of the most frequently dysregulated pathways in the human cancer biology [70].”
BackgroundScolnick, E. M., Rands, E., Williams, D., & Parks, W. P. (1973) · Journal of Virology · doi:10.1128/jvi.12.3.458-463.1973 · Cited by 252 · cited 1×
“The viral inoculum from leukemic rats was observed to induce sarcoma in newborn rats [14,15].”
BackgroundThe KRAS oncogene: Past, present, and future
Kranenburg, O. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.10.001 · Cited by 252
K-ras and p16 Aberrations Confer Poor Prognosis in Human Colorectal Cancer
Esteller, M., González, S., Risques, R. A., Marcuello, E., Mangues, R., Germà, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.299 · Cited by 234 · cited 1×
“KRAS mutations also carry a predictive role for the absence of response to anti-EGFR therapy in metastatic CRC and thus have a negative prognostic impact as well [27,28].”
BackgroundRecent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application
Yuan, X., Bu, H., Zhou, J., Yang, C.-Y., & Zhang, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00249 · Cited by 216 · cited 1×
“Overall, the primary oncogenic role of the SHP2 in the activation of the RAS/Raf pathway is to cause dephosphorylation of the tyrosine residues in the scaffolding proteins that result in the increased conversion of inactive RAS (RAS-GDP) to the activated RAS (RAS-GTP) [53].”
BackgroundWu, C.-J., O'Rourke, D. M., Feng, G.-S., Johnson, G. R., Wang, Q., & Greene, M. I. (2001) · Oncogene · doi:10.1038/sj.onc.1204699 · Cited by 178 · cited 2×
“The RAS/RAF/MEK/ERK and PI3K/AKT/mTOR are two of the most frequently dysregulated pathways in the human cancer biology [70].”
BackgroundRoss, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177 · cited 2×
“The KRAS depletion was not associated with any reciprocal feedback activation of MAPK pathway [72].”
BackgroundInteraction of SHP‐2 SH2 domains with PD‐1 ITSM induces PD‐1 dimerization and SHP‐2 activation
Patsoukis, N., Duke-Cohan, J. S., Chaudhri, A., Aksoylar, H.-I., Wang, Q., Council, A., Berg, A., Freeman, G. J., & Boussiotis, V. A. (2020) · Communications Biology · doi:10.1038/s42003-020-0845-0 · Cited by 169
The SHP-2 tyrosine phosphatase: Signaling mechanisms and biological functions
QU, C. K. (2000) · Cell Research · doi:10.1038/sj.cr.7290055 · Cited by 164 · cited 1×
“It functions as a protein tyrosine phosphatase that removes the tyrosine phosphorylation which is a crucial catalytic action and plays an important role in the multiple cellular functions including cellular proliferation, differentiation, and migration [52].”
BackgroundRegulation of the Mitogen-activated Protein Kinase Signaling Pathway by SHP2
Cunnick, J. M., Meng, S., Ren, Y., Desponts, C., Wang, H.-G., Djeu, J. Y., & Wu, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110547200 · Cited by 162 · cited 1×
“It is involved in various intracellular oncogenic signaling pathways, including the RAS/Raf/MAPK [46,47], PI3K/AKT [48], Jak/STAT [49], PD-1/PD-L1 [50], and mTOR pathways [51].”
BackgroundRole of proto-oncogene activation in carcinogenesis.
Anderson, M. W., Reynolds, S. H., You, M., & Maronpot, R. M. (1992) · Environmental Health Perspectives · doi:10.1289/ehp.929813 · Cited by 161
Identification of pyrazolopyridazinones as PDEδ inhibitors
Papke, B., Murarka, S., Vogel, H. A., Martín-Gago, P., Kovacevic, M., Truxius, D. C., Fansa, E. K., Ismail, S., Zimmermann, G., Heinelt, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11360 · Cited by 160 · cited 2×
“These inhibitors, such as Deltazinone 1 and Deltasonamide 1 and 2, competitively interact with the farnesyl-binding pocket of RAS [63,64].”
BackgroundGenetic and Epigenetic Events Generate Multiple Pathways in Colorectal Cancer Progression
Pancione, M., Remo, A., & Colantuoni, V. (2012) · Pathology Research International · doi:10.1155/2012/509348 · Cited by 160 · cited 1×
“In the majority of the cases, one pathway is the predominant pathogenic pathway; however complex interplay in certain cases could be seen [6].”
BackgroundSchmitz, K. J., Ademi, C., Bertram, S., Schmid, K. W., & Baba, H. A. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-0946-x · Cited by 157 · cited 2×
“Pelareorep can selectively infect the KRAS mutated CRC cells inducing lysis and promoting autophagy [67].”
BackgroundPhotoreceptor cGMP Phosphodiesterase δ Subunit (PDEδ) Functions as a Prenyl-binding Protein
Zhang, H., Liu, X.-H., Zhang, K., Chen, C.-K., Frederick, J. M., Prestwich, G. D., & Baehr, W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306559200 · Cited by 126 · cited 1×
“Prenyl-binding protein PDEδ is crucial in maintaining the spatial organization of RAS during the activation of signaling pathway [61,62].”
BackgroundValsasina, B., Beria, I., Alli, C., Alzani, R., Avanzi, N., Ballinari, D., Cappella, P., Caruso, M., Casolaro, A., Ciavolella, A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0765 · Cited by 123 · cited 1×
“One such drug is Onvansertib, which is a selective competitive inhibitor PLK-1 inhibitor [42].”
BackgroundmiR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer
Hong, Y., Liang, H., Ur-Rehman, U., Wang, Y., Zhang, W., Zhou, Y., Chen, S., Yu, M., Cui, S., Liu, M., et al. (2016) · Scientific Reports · doi:10.1038/srep37421 · Cited by 121 · cited 1×
“For example, an miR-96 is upregulated in lung, prostate, bladder, colorectal, and breast cancer however the same miR-96 is downregulated in pancreatic cancer [84].”
BackgroundBennouna, J., Lang, I., Valladares-Ayerbes, M., Boer, K., Adenis, A., Escudero, P., Kim, T.-Y., Pover, G. M., Morris, C. D., & Douillard, J.-Y. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9392-8 · Cited by 116 · cited 1×
“This study showed that selumetinib was well tolerated, and efficacy was comparable to capecitabine [76].”
ResultHiraoka, K., Inoue, T., Taylor, R. D., Watanabe, T., Koshikawa, N., Yoda, H., Shinohara, K., Takatori, A., Sugimoto, H., Maru, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7706 · Cited by 109 · cited 1×
“This agent is a pyrrole-imidazole polyamide indole-seco-CBI conjugate) which recognizes and alkylates the adenine residues on the template strand at codon 12 (GTT and GAT), exon 2 of mutated KRAS, producing strand cleavage which in turn decreases the proliferation rate of the CRC cell harboring G12D/G12 V mutation [44…”
BackgroundThe status and role of ErbB receptors in human cancer
Überall, I., Kolář, Z., Trojanec, R., Berkovcová, J., & Hajdúch, M. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.12.002 · Cited by 107 · cited 1×
“Moreover, the KRAS mutations in CRC lead to resistance to epidermal growth factor receptor (EGFR) directed therapies [13].”
BackgroundLi, Z.-N., Zhao, L., Yu, L.-F., & Wei, M.-J. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa022 · Cited by 104 · cited 1×
“The majority of the KRAS mutations in the CRC are located in codons 12 and 13 of exon 2 (80% are G12A, G12C, G12D, G12S, G12V, G13C, G13D), and less frequently in codon 61 of exon 3 (5% are Q61H, Q61L, and Q61R) and codon 146 of exon 4 (2% are A146T and A146V) [26].”
BackgroundMartinelli, E., Troiani, T., D'Aiuto, E., Morgillo, F., Vitagliano, D., Capasso, A., Costantino, S., Ciuffreda, L. P., Merolla, F., Vecchione, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28236 · Cited by 92 · cited 1×
“Similar to these studies, there are numerous pre-clinical and early phase studies showing the synergistic effect of MEK and P13K/mTOR [80,81].”
ResultWu, F., Niu, K., Cui, Y., Li, C., Lyu, M., Ren, Y., Chen, Y., Deng, H., Huang, L., Zheng, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01643-4 · Cited by 92 · cited 1×
“Four guanine bases bind with Hoogsteen hydrogen bonds to form a guanine tetrad plane (G-quartet), and then two or more G-quartet planes stack on top of each other to form a G4 structure [55] Figure 2.”
BackgroundMartín‐Gago, P., Fansa, E. K., Klein, C. H., Murarka, S., Janning, P., Schürmann, M., Metz, M., Ismail, S., Schultz‐Fademrecht, C., Baumann, M., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610957 · Cited by 88 · cited 2×
“This phenomenon is known as the Warburg’s effect [64].”
BackgroundBazan, V., Agnese, V., Corsale, S., Calò, V., Valerio, M. R., Latteri, M. A., Vieni, S., Grassi, N., Cicero, G., Dardanoni, G., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi908 · Cited by 84 · cited 1×
“In Colon cancers, approximately 45% of the cases carry a KRAS mutation [11,12].”
BackgroundKRAS G12C Mutations in NSCLC: From Target to Resistance
Addeo, A., Banna, G. L., & Friedlaender, A. (2021) · Cancers · doi:10.3390/cancers13112541 · Cited by 82 · cited 1×
“Few other direct KRAS inhibitors targeting KRAS G12C mutation in phase 1 clinical trials include GDC-6036 (NCT04449874), JNJ-74699157 (NCT04006301), and D-1553 (NCT04585035) [37].”
BackgroundKRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 74
Reovirus: A Targeted Therapeutic—Progress And Potential
Maitra, R., Ghalib, M. H., & Goel, S. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0157 · Cited by 74 · cited 2×
“The nuclear factor-erythroid 2 -related factor 2 (NRF2) and Kelch-like ECH-associated protein 1 (KEAP1) pathway protects the cells against oxidative and electrophilic stress and is tightly regulated under normal physiological conditions [66].”
BackgroundSelf-citationBlake, D. R., Vaseva, A. V., Hodge, R. G., Kline, M. P., Gilbert, T. S. K., Tyagi, V., Huang, D., Whiten, G. C., Larson, J. E., Wang, X., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav7259 · Cited by 71 · cited 5×
“Thus, targeting the MYC oncogene could be a potential therapeutic strategy for MYC-dependent cancers such as KRAS-mutant CRC [90].”
BackgroundInfluentialStructure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Huang, W.-Q., Lin, Q., Zhuang, X., Cai, L.-L., Ruan, R.-S., Lu, Z.-X., & Tzeng, C.-M. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140717105001 · Cited by 69 · cited 1×
“Src homolofy-2 Domain containing protein tyrosine phosphatase-2 (SHP2) is encoded by human PTPN11 gene and acts as a protein tyrosine phosphatase [45].”
BackgroundGupta, P., Zhang, Y., Zhang, X., Wang, Y., Lu, K. W., Hall, T., Peng, R., Yang, D., Xie, N., & Chen, Z. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487578 · Cited by 67 · cited 1×
“Voruciclib is a cyclin-dependent kinase (CDK) inhibitor and selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) [91].”
BackgroundOncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Jiffry, J., Thavornwatanayong, T., Rao, D., Fogel, E. J., Saytoo, D., Nahata, R., Guzik, H. M., Chaudhary, I., Augustine, T. A., Goel, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2385 · Cited by 56 · cited 1×
“Multiple experimental studies have shown that mutant KRAS enhances the activation of NRF2 antioxidant system and gene expression of the enzymes involved in the glutaminolysis, promoting tumorigenesis [67,68].”
BackgroundSelf-citationPitts, T. M., Newton, T. P., Bradshaw-Pierce, E. L., Addison, R., Arcaroli, J. J., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Purkey, A., Tentler, J. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113037 · Cited by 54 · cited 2×
“A pre-clinical study supporting the above results was done by Pitt et al. where they demonstrated suppression of tumor progression in CRC cell lines and tumor xenografts models with combinatory PI3K/mTOR inhibitor PF-502 and the MEK1/2 inhibitor PD-901 [79].”
BackgroundmiR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3
Zhou, Y., Dang, J., Chang, K.-Y., Yau, E., Aza-Blanc, P., Moscat, J., & Rana, T. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2936 · Cited by 54 · cited 1×
“identified FAK and LAMB3 as targets of miRNA-1298 and observed that an miRNA-1298 mimic was noxious to CRC and NSCLC mutant cells in both vitro and in vivo conditions [86].”
BackgroundFolding/unfolding kinetics of G-quadruplexes upstream of the P1 promoter of the human BCL-2 oncogene
Cheng, Y., Tang, Q., Li, Y., Zhang, Y., Zhao, C., Yan, J., & You, H. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007516 · Cited by 51
Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
Zocche, D. M., Ramirez, C., Fontao, F. M., Costa, L. D., & Redal, M. A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00116 · Cited by 50
Sabari, J. K., Park, H., Tolcher, A. W., Ou, S.-H. I., Garon, E. B., George, B., Janne, P. A., Moody, S. E., Tan, E. Y., Sen, S. K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.tps146 · Cited by 50 · cited 1×
“KRYSTAL-1 phase I/II clinical trial showed clinical activity in non-small cell lung cancer (NSCLC), CRC and other solid tumors such as pancreatic, endometrial, and ovarian cancers [34].”
BackgroundSelumetinib for the treatment of cancer
Ciombor, K. K., & Bekaii‐Saab, T. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.982275 · Cited by 47 · cited 1×
“Apart from CRC, selumetinib has been tested in Phase II setting in various gastrointestinal tumor types including HCC, biliary cancer, and pancreatic cancer [77].”
BackgroundT-Cell Transfer Therapy Targeting Mutant KRAS
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1616637 · Cited by 42
Lavrado, J., Borralho, P. M., Ohnmacht, S. A., Castro, R. E., Rodrigues, C. M. P., Moreira, R., dos Santos, D. J. V. A., Neidle, S., & Paulo, A. (2013) · ChemMedChem · doi:10.1002/cmdc.201300288 · Cited by 42
Goel, S., Ocean, A. J., Parakrama, R. Y., Ghalib, M. H., Chaudhary, I., Shah, U., Viswanathan, S., Kharkwal, H., Coffey, M. C., & Maitra, R. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1117 · Cited by 36 · cited 2×
“In a phase I clinical trial, pelareorep was combined with FOLFIRI/Bevacizumab, which showed the combination was able to induce 50% partial response in the enrolled patient cohort [69].”
BackgroundMethodSelf-citationKlein, C. H., Truxius, D. C., Vogel, H. A., Harizanova, J., Murarka, S., Martín‐Gago, P., & Bastiaens, P. I. H. (2018) · International Journal of Cancer · doi:10.1002/ijc.31859 · Cited by 32 · cited 2×
“Glutamine is an important amino acid necessary for the synthesizing glutamate via glutaminolysis, which in turn contributes to the tricarboxylic acid (TCA) cycle in the absence of glucose [65], thus making the cancer cells dependent on the glutaminemediated TCA cycle for their energy needs.”
BackgroundJones, D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3474 · Cited by 32 · cited 2×
“Another pre-clinical study using AZD4785 on a panel of various tumor cell lines including CRC showed potent downregulation of mutant KRAS [73].”
BackgroundE, J., Xing, J., Gong, H., He, J., & Zhang, W. (2015) · Tumor Biology · doi:10.1007/s13277-014-2667-5 · Cited by 29 · cited 1×
“Similar to these studies, there are numerous pre-clinical and early phase studies showing the synergistic effect of MEK and P13K/mTOR [80,81].”
ResultPorru, M., Artuso, S., Salvati, E., Bianco, A., Franceschin, M., Diodoro, M. G., Passeri, D., Orlandi, A., Savorani, F., D’Incalci, M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0253 · Cited by 29 · cited 3×
“identified natural alkaloids Indoloquinolines as potential G4-ligand compounds for targeting of KRAS in CRC [59,60].”
BackgroundSHP-2 Regulates Cell Growth by Controlling the mTOR/S6 Kinase 1 Pathway
Zito, C. I., Hui, Q., Blenis, J., & Bennett, A. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608338200 · Cited by 27 · cited 1×
“It is involved in various intracellular oncogenic signaling pathways, including the RAS/Raf/MAPK [46,47], PI3K/AKT [48], Jak/STAT [49], PD-1/PD-L1 [50], and mTOR pathways [51].”
BackgroundFakih, M., Desai, J., Kuboki, Y., Strickler, J. H., Price, T. J., Durm, G. A., Falchook, G. S., Denlinger, C. S., Krauss, J. C., Shapiro, G. I., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4018 · Cited by 26 · cited 1×
“Based on the significant objective response rate and duration of response in a phase 1 trial CodeBreak100 (NCT03600883) [31], it was approved in locally advanced or metastatic NSCLC.”
BackgroundEMICORON: A multi-targeting G4 ligand with a promising preclinical profile
Porru, M., Zizza, P., Franceschin, M., Leonetti, C., & Biroccio, A. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.11.010 · Cited by 24 · cited 1×
“identified natural alkaloids Indoloquinolines as potential G4-ligand compounds for targeting of KRAS in CRC [59,60].”
BackgroundKRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents
Ischenko, I., Zhi, J., Hayman, M. J., & Petrenko, O. (2017) · Oncotarget · doi:10.18632/oncotarget.14929 · Cited by 22 · cited 1×
“Thus, targeting the MYC oncogene could be a potential therapeutic strategy for MYC-dependent cancers such as KRAS-mutant CRC [90].”
BackgroundChandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L. D., Skoulidis, F., Ismail, S., Hedberg, C., Hanzal‐Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2462 · Cited by 11 · cited 1×
“Prenyl-binding protein PDEδ is crucial in maintaining the spatial organization of RAS during the activation of signaling pathway [61,62].”
BackgroundUp-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
Cimino, S. K., & Eng, C. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259287 · Cited by 9 · cited 1×
“This has resulted in the development and emergence of PLK-1inhibtors as next generation anti-cancer therapy [40].”
Background473P PLK1 expression and KRAS mutations in colorectal cancer
Jayachandran, P., Elliott, A., Battaglin, F., Lou, E., Zhang, W., Soni, S., Arai, H., Wang, J., Millstein, J., Lockhart, A. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.584 · Cited by 2 · cited 1×
“It has been observed that the RAS mutant cells are dependent on gene/proteins such as PLK-1, which are involved cell proliferation [41].”
BackgroundFedele, C., Li, S., Teng, K., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M., Hattori, T., Koide, A., et al. (2020) · bioRxiv · doi:10.1101/2020.05.30.125138 · Cited by 2 · cited 1×
“This catalytic function also makes SHP2 a critical facilitator in acquired resistance of the RAS signaling reactivation, to overcome pharmacological inhibition [54].”
BackgroundWiley, S. E., Su, Y., & Ge, Y. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-1962 · Cited by 1 · cited 2×
“presented the pre-clinical study at AACR virtual meeting [92].”
BackgroundEinstein, D. J., Choudhury, A. D., Saylor, P. J., Patterson, J. C., Croucher, P. I., Ridinger, M., Erlander, M. G., Yaffe, M. B., & Bubley, G. J. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.6_suppl.tps186 · Cited by 1
Research works printed but not linked: 1
- Therapeutics M. Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as Well as Initial MRTX1133 Preclinical Data 2020 Available online: https://ir.mirati.com/press-releases/press-release-details/2020/Mirati-Therapeutics-Reports-Investigational-Adagrasib-MRTX849-Preliminary-Data-Demonstrating-Tolerability-and-Durable-Anti-Tumor-Activity-as-well-as-Initial-MRTX1133-Preclinical-Data/default.aspx (accessed on 28 October 2021)
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Other approaches under investigation to target mutant KRAS in CRC include perturbing the interaction between KRAS and the plasma membrane, and the combined inhibition of downstream pathways [122].”
Li, C., Lau, H. C.-H., Zhang, X., & Yu, J. Q. (2022) · Biomedicines · doi:10.3390/biomedicines10071710 · Cited by 40
“Activation of KRAS is associated with various oncogenic pathways including PI3K/AKT/mTOR signaling to promote proliferation and to suppress apoptosis of tumor cells [27].”
BackgroundPostwala, H., Shah, Y., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02201-8 · Cited by 26
Nasioudis, D., Llauradó, M., Wong, N. K. Y., Powell, D. J., Mills, G. B., Westin, S. N., Fader, A. N., Carey, M. S., & Simpkins, F. A. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.08.007 · Cited by 19
IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Guruvaiah, P., & Gupta, R. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05384-4 · Cited by 14
“For a long time, KRAS was considered “undruggable,” but recent studies have identified therapies targeting specific KRAS mutations, especially in treating predominantly RAS-driven cancers [4].”
Background
Metadata
- Authors
- Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S.
- Affiliations
- Albert Einstein College of Medicine (US)
- Lander University (US)
- Yeshiva University (US)
- Corresponding author
- Goel, Sanjay
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-12-11
- Volume
- 13
- Issue
- 24
- Pages
- 6233
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8699097
- OpenAlex
- W4200211768
- Cited by
- 28
- References
- 96
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 1
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R21 AG058027 02 ( NIA))
- Yeshiva University (252869-252929, 2A4108)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- KRAS mutation, metastatic colorectal cancer, KRAS-targeted therapy, anti-EGFR therapy resistance, prognostic factors, personalized treatment, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.